Fibrosis is characterised by an exuberant wound healing response and the major cell type responsible is the myofibroblast. The myofibroblast is typified by excessive ECM production and contractile activity and is demarcated by alpha-smooth muscle actin expression. What has recently come to light is that the activation of the fibroblast to myofibroblast may be under epigenetic control, specifically methylation. Methylation of DNA is a conserved mechanism to precisely regulate gene expression in a specific context. Hypermethylation leads to gene repression and hypomethylation results in gene induction. Methylation abnormalities have recently been uncovered in fibrosis, both organ specific and widespread fibrosis. The fact that these methylation changes are rapid and reversible lends themselves amenable to therapeutic intervention. This review considers the role of methylation in fibrosis and the activation of the myofibroblasts and how this could be targeted for fibrosis. Fibrosis is of course currently intractable to therapeutics and is a leading cause of morbidity and mortality and is an urgent unmet clinical need.
Introduction
Fibrosis is characterised by an accumulation of extracellular matrix (ECM) proteins, particularly type I and type II collagen (Iredale, 2007) . This accumulation results in a hardening of the tissue, similar to what you would see as a result of scar tissue formation during the process of wound healing (Wynn, 2008) , however, in this case it is pathological and fibrosis of an organ will impair its function (Zeisberg and Kalluri, 2013) . In fibrotic tissues, myofibroblasts are the primary contributors to the excessive production of ECM proteins regardless of the aetiology (Zeisberg and Kalluri, 2013) . The fibrosis can be organ specific as in liver fibrosis or more widespread as in systemic sclerosis (SSc). Whether fibrosis is organ specific or diffuse it is a major cause of morbidity and mortality. Currently, there is no specific treatment and a deeper understanding of the activation of the myofibroblast is required. It is only recently that the molecular mechanisms of the switch between fibroblast and myofibroblast have come to light.
Myofibroblasts
Myofibroblasts produce ECM proteins such as collagen and ED-A fibronectin. However, the defining characteristic of the myofibroblast is its expression of α-smooth muscle actin (α-SMA); this gives the cell contractility, which allows the cell to aid in the process of wound healing by actively by pulling the two edges of a wound towards each other (Hinz et al., 2007) .
In a tissue that has been damaged, fibroblasts will differentiate into myofibroblasts and contribute to the repair of the damage (Hinz et al., 2007) . Persistent injury leads to the formation of scar tissue and fibrosis. Myofibroblasts can also arise from epithelial cells through a process known as epithelial-mesenchymal transition (EMT) (Wynn, 2008) ; in the liver, hepatic stellate cells (HSCs) are the major cell type from which myofibroblasts originate (Page et al., 2015) . The differentiation of HSCs to myofibroblasts is preceded by a specific set of gene changes and it is alteration in gene methylation that drives this process (Mann et al., 2010) . Methylation is an epigenetic modification that can spatially and temporally regulate gene expression. This review aims to examine the role of methylation in myofibroblasts and how this impacts fibrosis.
Pathogenesis of Fibrosis
Fibrosis can be triggered by injury to a tissue; this can be caused by toxicity, autoimmunity, the effect of cytokines, infection or trauma. Regardless of the cause, fibrosis arises when there is a failure of an injury to achieve resolution, thus leading to an accumulation of fibroblasts and overproduction of ECM proteins that can inhibit the function of organs. This loss of organ function can be fatal.
When there is damage to a tissue, resident fibroblasts (and some epithelial cells) adopt a myofibroblast phenotype and, through their contractility and secretion of ECM proteins, aid in wound repair. In fibrosis, the accumulation of myofibroblasts and ECM production becomes excessive and is also accompanied by damage to parenchymal tissues, changes to the microvasculature resulting in reduced perfusion and infiltration of mononuclear cells. Fibrosis can result in the loss of organ function as the resident parenchymal cells are replaced by myofibroblasts and ECM (Zeisberg and Kalluri, 2013) .
Methylation
Methylation of deoxyribonucleic acid (DNA) is the process of adding a methyl group to a nucleotide within the DNA. This methyl group is commonly donated by S-adenosyl-L-methionine (AdoMet) and its transfer is facilitated through the action of the DNA methyltransferase (DNMT) family of enzymes (Cheng and Roberts, 2001) . Dietary sources of methyl donors (e.g. folate) are important, with deficiency resulting in hypomethylation (Duthie et al., 2000) . In humans, four DNMT enzymes have been identified (see Table 1 ).
The methylation of DNA occurs predominantly at CpG dinucleotides, where a cytosine and guanine are separated by a single phosphate. The methylation occurs specifically on the 5 th Carbon atom of the cytosine ring (Meehan et al., 1992) , and is then referred to as 5-methylcytosine (5mC) (see figure 1); DNMT3a and DNMT3b both methylate DNA in this manner (Cheng and Roberts, 2001) . Reports on the degree of CpG island methylation vary, but numerous sources show it to be somewhere between 60-90% (Meehan et al., 1992; Robertson et al., 1999) .
The greatest frequency of CpG sequences is seen in CpG islands, sequences of repeating C and G nucleotides that are typically around 1000 base pairs in length. Approximately 70% of genes have a CpG island in their promotor region (Deaton and Bird, 2011) . DNMT3 and DNMT1 act synergistically, there is evidence to show that methylation by DNMT3 stimulates DNMT1 to further methylate the DNA, in one study this resulted in a fivefold increase in methylation activity over that of DNMT3 alone (Fatemi et al., 2002) . Alone, DNMT1 is recruited to sites of DNA where it acts to maintain methylation (Mortusewicz et al., 2005) . It also plays a role in DNA replication and knockdown of DNMT1 causes an arrest of intra-S phase DNA replication. It is thought that this mechanism acts to prevent demethylation that would arise from DNA replication in and absence of DNMT1 (Milutinovic et al., 2003) . DNMT3L has also been shown to cause a 20-fold increase to the catalytic activity of DNMT3a and DNMT3b (Gowher et al., 2005; Kareta et al., 2006) .
The methylation and demethylation of DNA is a form of epigenetic modification; a stable, inherited modification to DNA that does not alter the sequence, but results in a change in gene expression (Ciechomska et al., 2014) . DNA methylation is critically involved in X chromosome inactivation and the silencing of retroviral elements of the genome . Methylation of DNA can result in gene repression (Mohn et al., 2008) and hypomethylation of DNA is associated with elevated gene expression (Karouzakis et al., 2009) , however methylation does not always cause a change in expression. Gene repression is achieved through the action of methyl binding proteins such as methyl-Cap binding protein 2 (MeCP2) (Nan et al., 1998) , and other members of the methylCpG binding domain (MBD) family, which all share this domain, allowing them to bind to methylated-CpG sequences (Hendrich and Tweedie, 2003) . Repression of a gene is dependent on the density of the methylation, i.e. how frequently methylated-CpG sequences occur within the gene, and also on the location of the methylation in relation to the promoter region of the gene (Bian et al., 2013; Hsieh, 1994) Epigenetic changes have been linked to many diseases including cardiovascular disease (Webster et al., 2013) ; as well as colon, lung, breast and thyroid cancer, where large hypomethylated blocks of the genomes have been found (Hansen et al., 2011) and promoter hypermethylation of classic tumour suppressor genes are found. More recently, methylation changes have been associated with fibrotic diseases such as hepatic, pulmonary, renal and cardiac fibrosis (Mann et al., 2010; Rabinovich et al., 2012; Tampe et al., 2014; Xu et al., 2015) . Numerous genes have been found to be involved in this association and those referred to in this review are listed in Table 2 .
Komatsu et al. also found hypomethylation in the early stages of liver fibrosis. Global hypomethylation was observed, along with hypomethylation and upregulation of secreted phosphoprotein 1 (Spp1), a gene which induces inflammation. In addition, αSma, Col1a2, and Timp1 genes were also found to be hypomethylated and upregulated (Komatsu et al., 2012) . The upregulation of these genes, which are closely linked to fibrosis, coinciding with upregulation of Spp1 suggest that Spp1 may also play a role the processes of liver fibrosis. Interestingly it appears TIMP-1, a major fibrotic inducer is regulated by methylation as it can be modified by decatibine treatment (Vincent et al., 2015) .
In tissue samples from patients with idiopathic pulmonary fibrosis (IPF), it was found that 625 CpG islands were differentially methylated when compared to healthy tissue samples, with 91.2% of them being in intronic, exonic or intergenic regions and 8.8% of them in promoter regions. Many of these differentially methylated CpG islands were found to be in genes involved in apoptosis, cell morphogenesis, regulation of cellular biosynthetic processes, histone acetylation, cellular growth and proliferation, cell morphology, cancer and cell signaling. The IPF samples were then compared to samples from lung cancer patients; the lung cancer samples were found to have 2428 differentially methylated CpG islands when compared to healthy tissue samples. 65% of the differentially methylated CpG islands methylated in IPF samples were also seen in the lung cancer samples (Rabinovich et al., 2012) .
Methylation of the promoter region of the Thy-1 gene is associated with the myofibroblast phenotype in the lung, where expression of Thy-1 ceases and α-SMA expression is acquired. Using CCD19Lu lung fibroblasts, Robinson et al. found that hypoxia could induce global hypermethylation and that Thy-1 mRNA expression was suppressed. When the methylation was reversed with 5-aza-2'-deoxycytidine, Thy-1 expression was restored. This provides evidence that methylation alterations can influence myofibroblast differentiation (Robinson et al., 2012) . It has also been shown in idiopathic lung fibrosis that there is hypermethylation of the p14 ARF promoter compared to controls, leading to reduced expression. P14
ARF is a pro apoptotic protein, thus, its down regulation promotes resistance to apoptosis in IPF (Cisneros et al., 2012) .
In SSc, a prototypical fibrotic disease, in which the skin and lung are fibrotic, promoter hypermethylation of DKK1 and SFRP1 is found in myofibroblasts. This hypermethylation could be reversed with 5-Aza'C and, in a mouse model of fibrosis, pre-treatment with 5-Aza'C ameliorated fibrosis. This occurs because DKK1 and SFRP1 are Wnt antagonists; therefore, a reduction in their levels leads to unabated Wnt signalling, which is known to drive fibrosis (Dees et al., 2014) .
Furthermore, there has been described global and gene specific changes in dermal fibroblasts from SSc patients, including hypomethylation in RUNX genes (Altorok et al., 2015) . This is particularly interesting as both RUNX1 and RUNX2 have been shown to regulate tissue inhibitor of metalloproteinases 1 (TIMP-1) (Bertrand-Philippe et al., 2004) , which has a critical role in systemic sclerosis. A recent study in keloid fibroblasts, which are similar to SSc fibroblasts, with an abundance of ECM molecules, showed massive changes in global methylation with the majority being hypomethylated and 26% being hypermethylated (Jones et al., 2015) .
Altorok et al. also found numerous differentially methylated sites in SSc fibroblasts when compared to healthy controls. In diffuse cutaneous SSc, 2710 differentially methylated CpG sites were identified, with 61% being hypomethylated, and in limited cutaneous SSc, 1021 differentially methylated CpG sites were identified, with 90% being hypomethylated. Out of the differentially methylated sites in diffuse cutaneous SSc and limited cutaneous SSc, only 203 CpG sites were common between the two forms of the disease. These common sites of differential methylation between the two forms of the disease are likely key in the processes of fibrosis. In addition to the hypomethylation of the RUNX genes, COL23A1 and COL4A2, encoding collagens and MYO1E, encoding myosins, were also hypomethylated in both diffuse cutaneous SSc and limited cutaneous SSc (Altorok et al., 2015) .
Hypermethylation of the FLI1 promoter region has also been described in myofibroblasts from SSc patients, thus leading to its repression. FLI1 is a collagen suppressor gene and a negative regulator of fibrosis which is reduced in SSc patient's cells; in normal fibroblasts, reduction of FLI1 via siRNA results in excessive ECM production. SSc fibroblasts were also found to contain higher levels of DNMT1, histone deacetylase (HDAC)-1, HDAC-6, methyl-CpG DNA binding domain (MBD)-1 and MeCP2 than control fibroblasts, which is indicative of the epigenetic modifications occurring within them (Wang et al., 2006) .
Demethylation
DNA methylation marks are very stable and can be transmitted through generations, but they are not permanent and can be erased. The ten-eleven translocation (TET) family of proteins are responsible for the oxidation of 5mC into 5-hydroxymethylcytosine (5hmC) (Zhao et al., 2014) , and whilst 5mC is typically associated with gene silencing effects, 5hmC is associated with an increase in gene expression (Coppieters et al., 2014) . In addition, it has been found that TET can also covert 5mC into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011) . These alterations made to 5mC by TET are intermediate steps in the process of DNA demethylation; this can occur through the oxidation of 5mC and 5hmC into 5caC, which is then excised by thymine-DNA glycosylase, a base excision enzyme. From the current evidence, it is thought that this results in the initiation of the base-excision repair pathway, replacing what was originally 5mC with a non-methylated cytosine Maiti and Drohat, 2011) . There is also evidence that activation-induced deaminase/apolipoprotein B mRNA-editing enzyme complex (AID/APOBEC) deaminases promote demethylation of 5hmC (Guo et al., 2011) . TET can also cause DNA demethylation in a passive manner, DNMT1 shows lower activity at hemi-5hmC sites, meaning that the methylation cannot be maintained throughout the process of cell division (Valinluck and Sowers, 2007) . TET3 has recently been shown to regulate activation of hepatic stellate cells (HSCs) into myofibroblasts, silencing of TET3 was found to promote HSC activation and resulted in the downregulation of HIF-1A-AS1, a long non coding RNA; in addition, silencing of HIF-1A-AS1 was found to promote proliferation and reduce apoptosis in LX-2 cells (Zhang et al., 2014) .
It was recently shown that HSC transdifferentiation was accompanied by alteration in DNA methylation patterns; and that a decrease in DNMT3b resulted in a pro-fibrogenic phenotype in activated HSCs (Page et al., 2015) . In human livers affected by primary sclerosing cholangitis (PSC), where there is fibrosis of the intrahepatic bile ducts, it was shown that there is an increase in TETs (demethylating enzymes) and DNMTs; however hepatic protein expression of TET2 and TET3 ceased and there was also an induction of DNMT3b expression. Similar findings were also obtained from livers effected by alcoholic liver disease, although there was a reduction in TET2 expression (Page et al., 2015) . It is suggested that global and gene specific methylation changes precede the differentiation of the stellate cell. While Page et al. found a more methylated genome associated with liver myofibroblast activation, another group, Gotze et al., found in vitro that early activation of stellate cells was associated with global hypomethylation (Gotze et al., 2015) . These conflicting results could be a result of different genes having their methylation patterns altered; for example, hypomethylation of pro-fibrotic genes and hypermethylation of anti-fibrotic genes could both result in fibrosis. However, it also possible that this could simply be caused by the passage number of the cells that were used in each study, as it has been shown that methylation patterns can change with passage (Shmookler Reis and Goldstein, 1982) .
A gene specific hypermethylation occurs in phosphatase and tension homolog deleted on chromosome 10 (PTEN), a negative regulator of HSC activation. Hypermethylation of the PTEN promoter results in lessened expression, as well as enhanced phospho-extracellular-signal-regulated kinase (p-ERK) signalling, which is important in mediating fibrosis. Treatment with 5-aza-2′-deoxycytidine (5-Aza'C), a DNMT inhibitor, was found to decrease aberrant hypermethylation of the PTEN promoter, preventing the loss of expression seen in HSC activation. Furthermore, 5-Aza'C treatment prevented transforming growth factor-β (TGF-β)-mediated upregulation of Col1a1 and α-smooth muscle actin (α-SMA) mRNA as well as α-SMA protein (Bian et al., 2012) .
Bone morphogenetic protein endothelial cell precursor-derived regulator (BMPER), a member of the TGF-β superfamily, is an important regulator of fibroblast activation. It was found that BMPER is highly expressed in IPF lung fibroblasts, more so than in healthy lung fibroblasts. Demethylation using 5′-azacytidine resulted in a decrease in BMPER expression in both healthy and IPF fibroblasts; this shows that the expression of BMPER, and therefore fibroblast activation, is regulated through methylation and demethylation. Treatment with 5′-azacytidine to cause demethylation was also found to decrease expression of Collagen 1, hyaluronan and hyaluronan synthase 2 (Huan et al., 2015) . Hyaluronan is a polysaccharide component of the ECM (Laurent and Fraser, 1992) whilst hyaluronan synthase 2 is the enzyme which produces it (Jacobson et al., 2000) . It can therefore be established that a decrease in BMPER expression appears to result in reduced production of ECM components by lung fibroblasts. This decrease in ECM components also suggests a decrease in fibroblast migration as this is facilitated by the ECM (Huan et al., 2015) .
Angiogenic factor with G patch and FHA domains 1 (Aggf1) expression has been found to be suppressed in HSCs and downregulated in liver fibrosis. This suppression of Aggf1 expression was found to be a result of changes in DNA methylation, and treatment with 5'-azacytidine restored expression. Inducing overexpression of Aggf1 was shown to alleviate liver fibrosis both in mice and in HSC cultures. Aggf1 regulates liver fibrosis by binding to the inhibitory SMAD7 protein, this results in reduced binding of SMAD3 to gene promoters and subsequent inhibition of fibrogenesis. When SMAD7 was knocked down, HSC activation was restored (Zhou et al., 2016) . This again shows another gene that can induce fibrosis as a result of modification to DNA methylation.
MeCP2
MeCP2 is also of particular interest in fibrosis as there is evidence implicating it in the regulation of genes that play a vital role in the process (Bian et al., 2013) . MeCP2 is able to bind to a single methylated CpG dinucleotide and shows weaker binding to methylated non-CpG sequences; MeCP2 binding to methylated CpGs can result in gene repression, however, its suppressive capabilities rely on HDAC1 (Nan et al., 1998) . MeCP2 recruits HDAC1 to methylated DNA where it regulates heterochromatic association through interaction with a protein responsible for heterochromatic packaging, Heterochromatin protein-1 (Pandey et al., 2015) . Hemi-methylated DNA has been shown to be a poor substrate for MeCP2, meaning there will be less repression (Meehan et al., 1992) . It has been found in mouse models that MeCP2 also plays a role in gene activation. MeCP2-null mice had around ~85% of dysregulated genes in their hypothalamus downregulated (2184 out of the 2582 genes). At the site of activated gene promoters, MeCP2 is associated with CREB1, a transcriptional activator (Chahrour et al., 2008) .
One way in which MeCP2 has been implicated in the pathogenesis of fibrosis is through its ability to positively regulate expression of the enzyme absent, small, or homeotic disc1-like (ASH1L). ASH1L can methylate H3K4 (histone 3, lysine 4), which functions to upregulate the expression of certain genes, including α-SMA, collagen, TIMP1 and transforming growth factor-β1 (TGF-β1) (Bian et al., 2013) . These are key proteins associated with the myofibroblast phenotype.
In lung fibroblasts from mice with bleomycin-induced pulmonary fibrosis, Hu et al. found that MeCP2 binds to CpG islands in the α-SMA gene, specifically in the promoter region, intron 1 site 1 and intron 1 site 2; binding occurred regardless of whether they were methylated or unmethylated. However, MeCP2 showed a much higher affinity for the methylated promoter region and methylated intron 1 site 2. When over expression of MeCP2 was stimulated using a plasmid, a resulting rise in α-SMA expression was seen. siRNA induced repression of MeCP2 resulted in inhibition of α-SMA, even when treated with TGF-β, which normally stimulates α-SMA expression. This indicates that MeCP2 acts as an activator of α-SMA expression. However, it was also found methylation of the α-SMA promoter region inhibited the stimulatory effect of MeCP2 (Hu et al., 2011) .
The same study also found that mice deficient in MeCP2 showed lesser levels of fibrosis when treated with bleomycin than was seen in the wild-type (Hu et al., 2011) . In systemic sclerosis we have also seen elevated levels of MeCP2 in fibroblasts . We also showed that MeCP2 is induced in normal fibroblasts by the addition of TGF-β. Thus, it is clear that MeCP2 plays a role in fibrosis through regulation of gene expression.
TGF-β
TGF-β is also closely involved in the processes of fibrosis and plays a major role in the mediation of fibrosis. Fibroblasts that have been exposed to TGF-β express high levels of connective tissue growth factor (CTGF) and that TGF-β directly activates transcription of CTGF (Grotendorst et al., 1996) . TGF-β has been linked to an increase in the expression of COL1A1 in hepatic stellate cells (HSCs) (Garcia-Trevijano et al., 1999) and also COL1A2 in primary human fibroblasts (Chen et al., 1999) . It has also been shown that TGF-β stimulates fibroblast differentiation into the myofibroblast phenotype, mediated by extracellular-signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (p38 MAPK). This change in phenotype coincides with numerous changes to gene expression (Ding et al., 2008) . In cells from neonatal Sprague-Dawley rats, TGF-β induced upregulation of COL1A1 was also accompanied by decreased expression of DNMT1 and DNMT3a. This resulted in a decrease in the methylation levels at multiple CpG sites in the COL1A1 promoter (Pan et al., 2013) . However, Bechtel et al. found DMNT1 expression was induced by TGF-β (Bechtel et al., 2010) but again this may simply be caused by the passage number of the cells used in each study; alternatively it may be caused by differences in the type of cells used, since Pan et al. used cardiac cells and Bechtel et al. used renal cells and it has been established the methylation patterns vary in different tissues and individuals .
TGF-β also induces changes to methylation during EMT. Exposure to TGF-β resulted in an increase in the average methylation values of around 500 CpG islands located in or near gene promoters. Withdrawal of TGF-β stimulation resulted in methylation levels returning to their pre-TGF-β level. This suggests that continuing stimulation by TGF-β is required throughout the process of EMT (Cardenas et al., 2014) . Thus, TGF-β can induce both hypermethylation and hypomethylation, illustrating the complexities of the pathways that control and alter methylation patterns. Interestingly, treatment with 5-aza-2'-deoxycytidine abrogates the effects of TGF-β induced myofibroblasts in cardiac cells (Watson et al., 2014) .
Micro RNAs
Micro RNAs (miRNAs) are small, non-coding RNAs that are typically around 22-25 nucleotides in length. Their role is to mediate cleavage of messenger RNAs (mRNAs), destabilise mRNAs or repress translation, resulting in the regulation of gene expression. Many of these miRNAs regulate genes that are either pro-or anti-fibrotic; this is achieved through imperfect binding to the 3′ untranslated region (UTR) and the 5' UTR of their target mRNAs (O'Reilly, 2016) . It is now appreciated that while miRNAs are regulating gene expression, they themselves are regulated by methylation and cross talk occurs between the two.
MiRNA29 is closely linked to fibrogenesis and decreased levels have been associated with fibrosis of the heart, liver, kidney and skin as well as SSc. MiRNA29 has been shown to target the DNMT family, and ultimately results in abnormal methylation. Therefore, a reduction in miRNA 29 could result in hypermethylation of genes that regulate fibrosis. In idiopathic pulmonary fibrosis, there is a reduction in the levels of the miRNA-17-92 cluster. DNMT1 is a target gene for the miRNA-17-92 cluster, so a reduction in miRNAs of this cluster results in increased DNMT1 levels. Transfection of these miRNAs caused a reduction in DNMT1 levels and resulted in globally reduced DNA methylation (O'Reilly, 2016) .
Peroxisome proliferator-activated receptor-γ
Peroxisome proliferator-activated receptor-γ (PPAR-γ) has been inversely related to expression of collagen and is a critical regulator of liver fibrosis; it has been suggested as a 'master regulator' (Ghosh et al., 2008) .
MeCP2 has been shown to downregulate expression of PPAR-γ (see figure 2) through the promotion of methylation of H3K9 (histone 3, lysine 9) and enhancer of Zeste homolog 2 (EZH2) mediated methylation of H3K27 (histone 3, lysine 27), this allows for the chromatin silencer Heterochromatin Protein 1α (HP1α) to interact with the 5' end of the PPAR-γ gene (Mann et al., 2010) . This decrease in expression of PPAR-γ ultimately results in reduced inhibition of collagen synthesis and shows that MeCP2 has a critical role in the differentiation of liver myofibroblasts.
In rats, it has been found that ancestral liver damage led to adaptations in their offspring, making them more resistant to liver fibrosis. These adaptations were largely achieved through alterations to DNA methylation and histone deacetylation and resulted in an increase in PPAR-γ, which acts to impede fibrosis, as well a decrease in expression of profibrogenic TGF-β1 and decreased myofibroblast generation. Crosslinked qChIP analysis on sperm from these rats showed greater levels of H2A.Z and H3K27me3 incorporation into the chromatin at the PPAR-γ promoter (Zeybel et al., 2012) . However, how this occurs is not fully known and the mediators of the modulation of the sperm remain to be identified. These acquired and inheritable changes to gene expression reinforce the major role of epigenetic alterations in the processes of fibrosis. Of major interest in this study is the fact that in liver fibrosis patients, methylation at the PPAR-γ promoter could discern those with mild and severe liver fibrosis. It was found that those with severe liver fibrosis had higher levels of PPAR-γ promoter CpG methylation than those with mild fibrosis. This could underpin why some people progress to severe liver fibrosis and others have a more stable, mild disease. It has been known for some time that only a proportion of heavy drinkers develop alcoholic liver disease and this differential methylation may explain why. It has been shown in liver fibrosis that regression can occur if the damaging agent is removed. Therefore factors that promote regression of fibrosis are of interest. This is associated with reduction of TIMPs and induction of MMPs which will have a net effect of breaking down the collagenous scar. It may be in the case of myofibroblast regression that the cells have a reversal of their differentially methylated genes that promotes the reversal. This is yet to be proved experimentally but is an attractive hypothesis. As further research into TETs mediating the demethylation of DNA progresses this will be an interesting area.
Conclusion
Epigenetic changes, primarily methylation, and MeCP2 are intrinsic components in the process of fibrosis. With the evidence presented here showing global alterations to methylation, it seems that this may be one of the primary driving forces behind fibrogenesis and, in combination with MeCP2, HDAC1 and miRNAs, results in changes of expression of critical genes such as collagen, α-SMA, TIMP-1 and TGF-β. The evidence suggests that there is cross talk between methylation and other epigenetic modifications including miRNA, thus adding to the complexity found in myofibroblast activation and fibrogenesis.
Treatment of fibrosis remains to be a challenge; drugs that demethylate DNA, such as 5-Aza'C, may be repurposed for treatment of fibrosis. In cancer cell lines, treatment with the DNMT inhibitors azacytidine and decitabine was found to cause demethylation of genes in a non-random pattern, however, some CpGs appeared to have a resistance to drug-induced demethylation. This resistance was not seen in DNMT1, DNMT3b double knockout cells, indicating that the methylation of resistant CpGs is being maintained by these enzymes. It was also found that whole genome demethylation was higher than gene specific demethylation (Hagemann et al., 2011) .
Hydralazine, a vasodilator used to treat hypertension, has also been found to inhibit fibrosis. In C57BL/6 mice with renal fibrosis induced by unilateral ureteral obstruction, treatment with hydralazine produced lessened fibrosis compared to untreated controls and coincided with a reduced accumulation of fibroblasts. These results were mirrored in CD1 mice which received a dose of folic acid to induce renal fibrosis. It was also found that hydralazine treatment caused a reduction in Rasal1 methylation, caused by a reduction of DNMT1 expression and an induction of TET3-mediated hydroxymethylation . In HL-1 cells derived from mouse atrial cardiomyocytes, hydralazine also caused a decrease in methylation of the SERCA2 promoter by blocking DNMT1 (Kao et al., 2011) . Therefore, one of the greatest challenges in developing a demethylating treatment for fibrosis is ensuring that the desired genes are targeted. Whilst globally reducing methylation levels may potentially alleviate fibrosis, it could also have unintended side effects. To effectively develop and apply a demethylating drug for the treatment of fibrosis is likely going to require a more complete understanding of the processes and interactions between methylation patterns, miRNAs, the MBD family of proteins and HDACs as well as a deeper understanding of the genes involved. In the future, cell-free DNA methylation may possibly be used as a biomarker for fibrotic disease. Tables   Table 1. -Enzymes of the DNA methyltransferase family that methylate the 5 th carbon of cytosine.
Family Function

DNMT1
Preferentially methylates hemimethylated DNA. Maintains methylation.
DNMT2
Methylates cytosine 38 in the anticodon loop of aspartic acid transfer RNA. DNMT3a
Add methyl groups to DNA. DNMT3b
DNMT3L
Associates with DNMT3a & Dnnt3b and has been shown to increase catalytic activity.
TET1
Oxidise 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine.
TET2 TET3
References: (Cheng and Roberts, 2001; Fatemi et al., 2002; Goll et al., 2006; Kareta et al., 2006; Loenarz and Schofield, 2009) Figure 2 A simple depiction of collagen regulation, decreased levels of miRNA132 results in an increase in MeCP2 expression. MeCP2 then downregulates PPAR-γ expression ultimately causing increased collagen synthesis.
